Details
- AWS has made AWS HealthOmics generally available in the Asia Pacific (Tokyo) region, offering a HIPAA-eligible and ISMAP-compliant managed bioinformatics workflow service from data centers in Japan.
- The launch targets Japanese healthcare and life sciences organizations, including Eisai, which has begun validating HealthOmics for faster genomic analysis and more efficient multi-omics drug discovery workflows.
- HealthOmics provides fully managed private workflows supporting WDL, Nextflow, and CWL, elastic scaling to thousands of samples per day, and integration with Amazon SageMaker and Amazon Bedrock for AI-powered interpretation and agentic workflow automation.
- This Tokyo rollout aligns with Japan’s Genomic Medicine Promotion Act and large-scale initiatives such as Biobank Network Japan and the Japan Genomic Medicine Promotion Organization, which are driving whole-genome sequencing and demanding secure, in-country infrastructure for exponentially growing datasets.
- AWS HealthOmics is already used globally by organizations like Roche, Natera, and Genomics England, and the Tokyo expansion complements AWS’s broader 2.26 trillion yen cloud infrastructure investment in Japan from 2024–2027 and its "Journey for 2030" healthcare data strategy.
Impact
The Tokyo-region launch strengthens Japan’s genomic medicine and precision drug discovery stack by pairing compliant, in-country data residency with AI-native bioinformatics workflows. Over the next 12–24 months, this is likely to accelerate adoption of whole-genome analysis in clinical and research settings, deepen use of AWS AI services in multi-omics R&D, and attract further investment into data-driven healthcare platforms built on AWS in Japan.
